News and Trends 14 Aug 2019 Engineered Skin Shows Potential to Treat Burns in Phase I Engineered skin tissue, developed as a regenerative medicine by the UK-US pharma company Mallinckrodt, has reduced the need for skin grafts in burns victims in a phase Ib trial. The phase I trial tested Mallinckrodt’s engineered skin treatment in 29 patients suffering from deep second degree burns. Patients with these burns have damage to the […] August 14, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Aug 2019 AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise The US company AskBio has acquired the Edinburgh-based Synpromics to pool their gene therapy technologies and produce inducible gene therapies that target particular organs or cells. AskBio specializes in developing viral vectors that carry gene therapies into cells, such as adeno-associated virus, whereas Synpromics develops DNA sequences called promoters that drive the expression of gene […] August 13, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Aug 2019 Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months The UK biotech Autolus’ shares have slumped as construction delays from a new manufacturing site have pushed back its CAR-T cell immunotherapy programs. Autolus is developing treatments for blood cancer that involve engineering patients’ own immune cells to kill cancer cells, known as autologous CAR-T cell immunotherapies. Earlier this year, Autolus licensed a new manufacturing […] August 12, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 9 Aug 2019 This Biotech Cleans up Drugs from Sewage Using Enzymes We’re visiting Uppsala, Sweden, this week. This city is home to Pharem Biotech, a company developing enzymes to break down drug residues contaminating wastewater. Mission: To remove drug residue from sewage water by developing enzymes that are modified to be 200 times more effective than natural enzymes. This technology could reduce the ecological and health […] August 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Aug 2019 Late-Stage Clinical Trial Troubles for Dry Eye Disease Drug A drug developed by the UK company Topivert Pharma has failed to reduce eyeball grittiness sensations in patients with dry eye disease in a phase II/III trial. The trial tested Topivert’s small molecule drug given as eyedrops to 202 patients suffering from dry eye disease, a condition where not enough tears are produced to lubricate […] August 7, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 7 Aug 2019 Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience In less than two years, Orchard Therapeutics has changed from a small, relatively unknown UK biotech specializing in gene therapy into a billion euro company listed on the Nasdaq. This is in no small part due to the skills and experience of Mark Rothera, its CEO and President, who joined the company in 2017. Orchard […] August 7, 2019 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Aug 2019 ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment Two companies based in Lausanne, Switzerland — ADC Therapeutics and the genomics company SOPHiA Genetics — have signed a deal to identify patients most likely to respond to a blood cancer drug. ADC Therapeutics will send SOPHiA Genetics blood samples collected from an ongoing phase II trial. The trial is testing a treatment for patients […] August 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 5 Aug 2019 Phase II Promise for Inhaled Chronic Lung Disease Treatment A first-in-class inhaled drug developed by the UK biotech Verona Pharma improved lung function in a phase II trial treating the lung condition chronic obstructive pulmonary disease. The 37 patients in the trial had chronic obstructive pulmonary disease (COPD), a common lung condition that involves a tightening of the lung airways and breathlessness. Verona Pharma […] August 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2019 Oncolytic Virus for Liver Cancer Ruled Futile in Phase III A phase III trial testing an oncolytic virus treatment for liver cancer, developed by the French biotech Transgene, has been discontinued after interim analyses concluded that the treatment was unlikely to succeed. Originally expected to finish in 2020, the phase III trial tested the oncolytic virus treatment Pexa-Vec in patients with the liver cancer hepatocellular […] August 2, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 2 Aug 2019 This Biotech Uses Messenger RNA to Treat Lethal Lung Inflammation Based close to Berlin, Germany, the biotech startup Pantherna Therapeutics is developing a messenger RNA drug to treat a life-threatening lung condition that requires mechanical ventilation. Mission: To develop a messenger RNA (mRNA) drug to treat acute respiratory distress syndrome, an inflammatory lung reaction that kills up to half of patients with the condition. Acute […] August 2, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 1 Aug 2019 Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed as the UK company Atlantic Healthcare’s RNA drug has proved ineffective in a phase III trial. The trial tested Atlantic Healthcare’s RNA drug alicaforsen as a treatment for patients with pouchitis. Patients with this condition have their colon surgically replaced […] August 1, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 1 Aug 2019 How to Use Case Studies to Take Your Life Science Marketing Strategy to the Next Level To build a great relationship with a business partner, laying a foundation of trust is essential. But how can a potential partner trust you if they have no concept of how you work? Case studies can help communicate trust and show your potential partner how they can improve their life science marketing strategy by working […] August 1, 2019 - 6 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email